Personalis
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Myriad Genetics to Market Personalis Biomarker Discovery Platform to Pharma Customers
Myriad will market the ImmunoID NeXT immunogenomics discovery platform to pharma customers using its MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and/or MyChoice CDx assays.
Earnings Roundup: Personalis, Sophia Genetics, Standard BioTools, OraSure, Biodesix, Enzo, More
These genomics and molecular diagnostics firms posted their quarterly financial results this week.
New Products Posted to GenomeWeb: OGT, IntelliSeq, Personalis, NeoGenomics, Quanterix, C2N, More
New products and services posted to GenomeWeb for the week of Oct. 23, 2023
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.